文献速递泌尿男性生殖肿瘤

醋酸阿比特龙联合泼尼松治疗新诊断高危转移性去势敏感性前列腺癌(LATITUDE):随机双盲3期试验最终总生存分析

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-04-12

LATITUDE研究最终分析显示,在235个中心、34个国家纳入的1199例新诊断高危转移性去势敏感性前列腺癌患者中,醋酸阿比特龙联合泼尼松加ADT较安慰剂加ADT显著延长总生存期,中位随访51.8个月,死亡风险比为0.66。安全性方面,联合组高血压和低钾血症等3-4级不良事件发生率较高,但总体可管理。

要点

  • 联合组中位总生存期为53.3个月,安慰剂组为36.5个月,HR=0.66(95%CI 0.56-0.78,p<0.0001)。
  • 联合组3-4级高血压发生率为21%,安慰剂组为10%,交叉组为4%。
  • 联合组严重不良事件发生率为32%,安慰剂组为25%,交叉组为6%。

核心结论

  • 醋酸阿比特龙联合泼尼松加ADT较安慰剂加ADT显著延长新诊断高危mCSPC男性患者的总生存期,且安全性可控。
  • 这些发现支持将醋酸阿比特龙联合泼尼松作为高危mCSPC患者的标准治疗。

研究设计与样本

  • 多中心、随机、双盲、3期试验,在34个国家235个中心进行。
  • 纳入1199例新诊断、组织学或细胞学证实的前列腺癌伴转移、ECOG体能状态0-2分、且至少具有两项高危预后因素(Gleason评分≥8、骨扫描≥3个病灶、或可测量内脏转移除外淋巴结转移)的男性患者。
  • 患者按1:1随机分配至醋酸阿比特龙(1000 mg)每日一次口服联合泼尼松(5 mg)每日一次口服加ADT组(n=597)或匹配安慰剂加ADT组(n=602),每周期28天。
  • 随机化按国家分层,使用置换区组随机化,分层因素为内脏疾病和ECOG体能状态。
  • 主要终点总生存期在意向治疗人群中评估。

主要发现

  • 中位随访51.8个月(IQR 47.2-57.0),共发生618例死亡:联合组275例(46%,275/597),安慰剂组343例(57%,343/602)。
  • 联合组中位总生存期为53.3个月(95%CI 48.2-未达到),安慰剂组为36.5个月(95%CI 33.5-40.0),HR=0.66(95%CI 0.56-0.78;p<0.0001)。
  • 最常见的3-4级不良事件为高血压:联合组125例(21%),安慰剂组60例(10%),交叉组3例(4%,3/72);低钾血症:联合组70例(12%),安慰剂组10例(2%),交叉组2例(3%)。
  • 任何级别的严重不良事件:联合组192例(32%,192/597),安慰剂组151例(25%,151/602),交叉组4例(6%,4/72)。
  • 治疗相关死亡:联合组3例(<1%,胃溃疡穿孔、猝死、脑血管意外),安慰剂组3例(<1%,猝死、脑血管意外、肺炎),交叉组0例。

临床怎么用

  • 作者认为,这些发现支持将醋酸阿比特龙联合泼尼松作为高危mCSPC患者的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the interim analyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and radiographic progression-free survival compared with placebos plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (mCSPC). Here, we present long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT from the final analysis of the LATITUDE study. METHODS: This is a multicentre, randomised, double-blind, phase 3 trial done at 235 sites in 34 countries. Eligible patients (men aged ≥18 years) had newly diagnosed, histologically or cytologically confirmed prostate cancer with metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and at least two of the three high-risk prognostic factors (Gleason score of ≥8, presence of three or more lesions on bone scan, or presence of measurable visceral metastasis except lymph node metastasis). Patients were randomly assigned (1:1) to receive abiraterone acetate (1000 mg) once daily orally plus prednisone (5 mg) once daily orally and ADT (abiraterone acetate plus prednisone group) or matching placebos plus ADT (placebo group); each treatment cycle was 28 days. Randomisation was done by a centralised interactive web response system in a country-by-country scheme using permuted block randomisation, stratified by presence of visceral disease and ECOG performance status. The coprimary endpoint of overall survival was assessed in the intention-to-treat population. This study is registered at ClinicalTrials.gov, number NCT01715285 and is complete. FINDINGS: Between Feb 12, 2013, and Dec 11, 2014, 1209 patients were screened, of whom ten were ineligible because of study site violations. 1199 patients were randomly assigned to either the abiraterone acetate plus prednisone group (n=597) or placebo group (n=602). After the results of the first interim analysis (cutoff date Oct 31, 2016), the study was unmasked to patients and investigators, and patients in the placebo group were allowed to cross over to receive abiraterone acetate and prednisone plus ADT treatment as per a protocol amendment (Feb 15, 2017) in an open-label extension phase of the study (up to 18 months from the protocol amendment). This final analysis (data cutoff Aug 15, 2018) was done after a median follow-up of 51·8 months (IQR 47·2-57·0) and 618 deaths (275 [46%] of 597 in the abiraterone acetate plus prednisone group and 343 [57%] of 602 in the placebo group). Overall survival was significantly longer in the abiraterone acetate plus prednisone group (median 53·3 months [95% CI 48·2-not reached]) than in the placebo group (36·5 months [33·5-40·0]), with a hazard ratio of 0·66 (95% CI 0·56-0·78; p<0·0001). The most common grade 3-4 adverse events were hypertension (125 [21%] in the abiraterone acetate plus prednisone group vs 60 [10%] in the placebo group vs three [4%] in the 72 patients who crossed over from placebo to abiraterone acetate plus prednisone) and hypokalaemia (70 [12%] vs ten [2%] vs two [3%]). Serious adverse events of any grade occurred in 192 (32%) of 597 patients in the abiraterone acetate plus prednisone group, 151 (25%) of 602 in the placebo group, and four (6%) of 72 in the crossover group. The most common treatment-related serious adverse event was hypokalaemia (four [1%] patients in the abiraterone acetate plus prednisone group and none in the other groups). Treatment-related deaths occurred in three (<1%) patients each in the abiraterone acetate plus prednisone group (gastric ulcer perforation, sudden death, and cerebrovascular accident) and the placebo group (sudden death, cerebrovascular accident, and pneumonia), with none in the crossover group. INTERPRETATION: The combination of abiraterone acetate plus prednisone with ADT was associated with significantly longer overall survival than placebos plus ADT in men with newly diagnosed high-risk mCSPC and had a manageable safety profile. These findings support the use of abiraterone acetate plus prednisone as a standard of care in patients with high-risk mCSPC. FUNDING: Janssen Research & Development.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019. PMID: 30987939. doi:10.1016/S1470-2045(19)30082-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。